Candace Taylor

Dynamic clinical research professional with extensive experience at Methodist Children's Hospital. Proven track record in team leadership and quality assurance, excelling in site management and problem-solving. Adept at driving successful research initiatives, ensuring compliance, and enhancing operational efficiency. Committed to advancing pediatric care through innovative research solutions.

Published Articles

1. Swinney RM, Wall D, Thomas P, Grimley M, Taylor C, Tomlinson GE. Familial Childhood Leukemia Cluster with Multiple Aggressive Early- Onset Hematological Malignancies. Leuk Lymphoma. 2006 May;47(5):930-2
2. Impact of Sepax-Based Umbilical Cord Blood Graft Processing on Clinical Outcomes. Troy C. Quigg, Candace Taylor, Juan Huerta, Jose C. Cruz. February 2016 DOI: 10.1016/j.bbmt.2015.11.903

Published Abstracts

1. Tbo-Filgrastim Versus Filgrastim during Mobilization and Neutrophil Engraftment in Autologous Stem Cell Transplantation. Mohammed M. Elayan, Jose M. Magraner, Justin G. Horowitz, Candace Taylor, Penny McGavran, Paul J. Shaughnessy, Carlos Bachier- Biology of Blood and Marrow Transplantation, Published in issue: February 2015
2. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium Trial - Michael
A Pulsipher, Bryan Langholz, Donna A Wall, Kirk R. Schultz, Nancy Bunin, William
L. Carroll, Elizabeth Raetz, Sharon Gardner, Julie M. Gastier-Foster, Denise Howrie, Rakesh K. Goyal, James G. Douglas, Michael Borowitz, Yvonne Barnes, David T.
Teachey, Candace Taylor, Stephan A Grupp Blood. 2014 Mar 27; 123(13): 2017-2025

3. A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431- Michael A Pulsipher, MD1, Bryan Langholz, PhD2*, Donna A. Wall, MD3, Kirk R. Schultz, MD4, Nancy Bunin, MOS, William L. Carroll, MD6, Elizabeth A Raetz, MD7*, Sharon Gardner, MD8, Julie M. Gastier-Foster, PhD9, Denise Howrie, PharmD10*, Rakesh Goyal, MD, MRCP11, Douglas James, MD, MRCP12*, Michael J. Borowitz, MD, PhO13, Yvonne Jean Barnes, RN MSN CPNP14*, Shivanand R. Patil, PhD15, David T Teachey, MD16*, Candace Taylor, CCRP17* and Stephan A Grupp, MD, PhD18*December 2011
4. Primary Graft Failure (GF) after Unrelated Donor Cord Blood Transplants (UCBT): Risk Factors and Management. Ka Wah Chan, Michael S. Grimley, Candace Taylor, Donna A. Wall
Blood 2006 108:44;
5. Grimley MS., Taylor C., Wall DA., Frequency and Magnitude of Dose Adjustment of IV Busulfan in Targeted Dosing Strategy for Pediatric Allogeneic Transplantation. Tandem BMT Meeting Orlando, FL February 2004

Oral and Poster Presentations

1. Troy C. Quigg, DO, MS, Sherri Shade, RN, CCRC, Candace Taylor, Cody Ginn, MLS (ASCP), Juan
C. Huerta, BS, MT, Alfred G. Nanez, BS, MT (ASCP) BB, Lisa M. Madden, MD, MS, Cesar 0. Freytes, MD, Behyar Zoghi, MD, PhD, Ju-Hsien Chao, DO, Paul J. Shaughnessy, MD, Jose Carlos Cruz, MD, and Michael J. Eckrich, MD, MPH. Sepox-processed umbilical cord blood grafts ore associated with excellent clinical outcomes. 2018 BMT Tandem Meetings (ASBMT/CIBMTR), Salt Lake City, Utah (Poster)
2. Michael J Eckrich MD, MPH, Lisa Madden MD MS, Candace Taylor, Christina Matheny NP, Erica Garcia-Frausto DNP, Ka-Wah Chan MD and Troy Quigg DO MS. Reduced-intensity ollogeneic stem cell transplant/or sickle cell disease in pediatrics: A single institution experience. 2018 BMT Tandem Meetings (ASBMT/ClBMTR), Salt Lake City, Utah (Poster)
3. Troy C. Quigg, DO, MS, Candace Taylor, CCRP, Juan C. Huerta, BS, MT, Alfred G. Nanez, BS, MT (ASCP) BB, Robert

2001- present

• Certified Clinical Research Professional, SoCRA - 2001- present